lung disease

Tracking lung macrophages

A new technique will allow researchers to track subsets of immune cells that patrol and defend the lungs, to better understand the roles of these cells during lung inflammation, infection and injury.

Cell-free hemoglobin in pulmonary hypertension

Cell-free hemoglobin generated by the lungs may be a therapeutic target for treating pulmonary arterial hypertension, Vanderbilt researchers found.

Gut microbiota and lung fibrosis

Microorganisms residing in the gut influence the severity of lung fibrosis in mouse models, suggesting that modifying the gut microbiota may offer therapeutic benefit for patients.

New clue to lung scarring

Vanderbilt neonatology team pinpoints signaling pathways involved in the progressive lung fibrosis that occurs in rare genetic diseases.

Device offers less invasive option to treat emphysema

Life with emphysema, a lung condition that causes shortness of breath, can be miserable. People with advanced emphysema, a form of chronic obstructive pulmonary disease (COPD), are so short of breath they may need supplemental oxygen just to walk from room to room. They often have trouble with everyday tasks like bathing or cooking a meal.

By Nancy Humphrey

March 27, 2019

VUMC and TGen receive $6.1 million in grants to study deadly lung disease

Vanderbilt University Medical Center, the Translational Genomics Research Institute (TGen), an affiliate of City of Hope and the Norton Thoracic Institute at St. Joseph’s Hospital and Medical Center in Arizona, have received a $3.5 million federal grant to study the cause of idiopathic pulmonary fibrosis (IPF) the nation’s most common and severe form of fibrotic lung disease.